We reasoned that the identification of kinase inhibitors that could effectively inhibit CTGF expression could provide useful information on the mechanism involving the regulation of CTGF expression, as well as therapeutic insights into targeting CAFs in GC therapy. This evidence concerns the gene CCN2 and gastric cancer.